Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma.
Azad
Arun
A
Herbertson
Rebecca A
RA
Pook
David
D
White
Shane
S
Mitchell
Paul L R
PL
Tebbutt
Niall C
NC
D000284:Administration, Oral; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D018365:Neoplasm, Residual / Q000188:drug therapy; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009841:Oligonucleotides; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D018714:Radiotherapy, Adjuvant; D013945:Thymoma / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary* / Q000601:surgery; D013953:Thymus Neoplasms / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D007211:Indoles; D009841:Oligonucleotides; D009536:Niacinamide; C519562:imetelstat